[The combination of chronic myeloid leukemia and multiple myeloma in one patient]
| Autor: | N A, Romanenko, S S, Bessmel'tsev, V Iu, Udal'eva, M N, Zenina, I S, Martynkevich, V I, Rugal', K M, Abdulkadyrov |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Induction Chemotherapy
Middle Aged Boronic Acids Dexamethasone Piperazines Bortezomib Polyneuropathies Pyrimidines Recurrence Karyotyping Leukemia Myelogenous Chronic BCR-ABL Positive Pyrazines Antineoplastic Combined Chemotherapy Protocols Benzamides Biomarkers Tumor Imatinib Mesylate Humans Female Molecular Targeted Therapy Multiple Myeloma Watchful Waiting |
| Zdroj: | Voprosy onkologii. 59(2) |
| ISSN: | 0507-3758 |
| Popis: | The article describes the clinical observation of a patient with simultaneous course of lymphoid and myeloid neoplasms. The patient developed two diseases--chronic myeloid leukemia (CML) and multiple myeloma (MM), which were confirmed by corroborated hemogram, myelogram, immunophenotyping of bone marrow cells, biopsy, immunohistochemical, cytogenetic, biochemical and radiological studies. Target therapy of CML with tyrosine kinase inhibitors (imatinib at the standard dose of 400 mg per day) has provided a complete cytogenetic remission at 6 months and major molecular response at 18 months of treatment. Administration of 2 courses of programmed treatment "BD"(bortezomib + dexamethasone) resulted in a very good partial response, which was maintained through a year and a half. However, against the background of programmed treatment there were developed complications as polyneuropathy of grade 2, which was treated with thioctacide, milgamy, and anemia of grade 2, successfully treated with epoetin beta. Subsequently, the patient was administered continuously with imatinib 400 mg that kept the major molecular response. Relapsed MM was revealed in 20 months and confirmed by a full clinical and hematological examination. The absence of organ dysfunction allowed choosing a supervisory tactics for the patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|